Skip to main content
. 2020 Oct 14;2020(10):CD012796. doi: 10.1002/14651858.CD012796.pub2

Comparison 12. Sunitinib versus Atezolizumab.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
12.1 Progression‐free survival 1   Hazard Ratio (IV, Random, 95% CI) Totals not selected
12.2 Overall survival 1   Hazard Ratio (IV, Random, 95% CI) Totals not selected
12.3 Serious adverse events (Grade 3 or 4) 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected
12.4 Health‐related quality of life 1   Mean Difference (IV, Random, 95% CI) Totals not selected
12.5 Response rate 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected
12.6 Minor adverse events (Grade 1 or 2) 1   Risk Ratio (M‐H, Random, 95% CI) Totals not selected